117 , 202 A highly significant reduction of the fibrosis score by stage without worsening of the NAS was achieved in 24.2% of the patients in the 80 mg and 25.9% of those in the 100 mg resmetirom group compared with 14.2% in the placebo group.
← all excerpts
Antifibrotic therapies for metabolic dysfunction-associated steatotic liver disease.
1
—
—